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Abstract
Purpose - The aim of this meta-analysis is to review the efficacy of atypical antipsychotics in
combination with clozapine. Previous meta-analysis have assessed the use of both typical and
atypical antipsychotics in combination with clozapine, combination treatment being withheld only
for those patients deemed treatment resistant.
Design/methodology/approach - We conducted the meta-analysis in accordance with the Pre-
ferred Reporting Items for Sytematic Reviews and Meta-Analyses (PRISMA) guidelines. The fol-
lowing inclusion criteria was applied; i.) Trials and reports that were written in English; ii.) An
antipsychotic was added to clozapine; ii.) The non-clozapine antipsychotic was atypical; iii.) Trials
were randomised, double-blind placebo controlled; iv.) Trials were conducted between the years
of 2000 and 2015
Findings - The effect sizes gained from analysis showed a small benefit of combination therapy
over clozapine monotherapy.
Research limitations/implications - The initial trial search unveiled 1,412 studies. After the in-
clusion and exclusion criteria was applied, 10 trials were used in this meta-analysis.
Practical implications - the recommendation of this analysis that alternative medications be
sought in order to treat patients who have a sub-optimal response to clozapine with a combi-
nation other than two second generation antipsychotics. This route should only be used once all
other treatment options have been exhausted
Originality/value - This work extends existing meta-analysis by incorporating data from more re-
cent trials.
Keywords Schizophrenia, Atypical, Antipsychotics, Combination, risperidone, aripiprazole
Paper type Research paper
Introduction
It is generally accepted that over the course of their lifetime, about 1% of the UK population will
develop schizophrenia, although one study suggests the true figure may be closer to 0.72% (Saha
et al., 2005). Furthermore, we should be clear as to the working definition of treatment resistant
schizophrenia as defined by Howes et al in their systematic review of randomized antipsychotic
clinical trials where definitions of treatment resistance were extracted (Howes et al., 2017).
Clozapine is an atypical antipsychotic reserved only for those patients who have been adequately
trialled unsuccessfully on at least two previous antipsychotics(NICE178, 2014). The failure is usu-
ally due to hematological side effects (Pirmohamed and Park, 1997). One of several side-effects
that can be attributed to non-clozapine atypical antipsychotics. A patient should trialled on cloza-
pine for a minimum of 8-10 weeks before being classed as treatment resistant.
The term Treatment Resistant Schizophrenia was first coined by Kane et al (Kane et al., 1988),
where it was determined that those patients who have not responded to two previous antipsychotic
therapies should be given clozapine in doses equivalent of up 1000mg of chlorpromazine. The
benefits of clozapine include reduced risk of suicide (Meltzer et al., 2003) and overall mortality
(Sernyak et al., 2001) in schizophrenia. Antipsychotic polypharmacy in which more than one an-
tipsychotic drug is used to treat a patient‘s schizophrenia is becoming more common in practice
(Langan and Shajahan, 2010), however it is advised against due to the increased risk of side ef-
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fects such as sedation, weight gain, extra-pyramidal side effects and blood disorders (Dold and
Leucht, 2014). It has been recommended by the National Institute of Clinical Excellence (NICE)
that combining antipsychotic medication should not be initiated unless it is to change one medi-
cation to another, even this should only be for a short period of time (NICE82, 2008). However,
despite the risks of polyphramacy, the basis for using clozapine is because of the association with
significant clinical improvement relative to usual treatment, along with reduced suicidal thoughts
and reduced rehospitalization rates.
The aim of this meta-analysis is to review the efficacy of atypical antipsychotics in combination
with clozapine.
Methods
This meta-analysis was devised in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009). Databases searched in-
clude; Science Direct, PubMed, PubMed Central, Cochrane Library and the clinical trials register.
The search for material was updated in June 2017. Key terms used in the search were; clozapine,
augmentation, combination, treatment-resistant schizophrenia, refractory schizophrenia as well as
the generic names of all the atypical antipsychotics.
Inclusion criteria.
The following inclusion criteria was applied; i.) Trials and reports that were written in English; ii.)
An antipsychotic was added to clozapine; ii.) The non-clozapine antipsychotic was atypical; iii.)
Trials were randomised, double-blind placebo controlled; iv.) Trials were conducted between the
years of 2000 and 2015.
Exclusion criteria.
Trials were excluded on the basis; i.) Drugs were not in combination with clozapine but were a
comparison; ii.) Drugs were compared to each other and not a placebo; iii.) Trials were open and
single-blind; iv.) Case Reviews.
Statistical analysis.
Particular rating scales were used when developing the forest plots in order to obtain an effect size,
we used the random-effects model as we believed the different studies had different effect sizes.
The fixed-effect model assumes some heterogeneity of effect and that every study has a com-
mon true effect size, this cannot be assumed and the random-effects model is more appropriate
under these circumstances. The Positive and Negative Symptom Scale (PANSS) (Kay, Fiszbein
and Opler, 1987) and The Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962)
were used to assess the efficacy of the drugs on schizophrenia. Some papers used a mixture of
scales and some used only PANNS or BPRS, we used the method devised by Leucht to convert
between them (Leucht et al., 2013). The Scale for the Assessment of Negative Symptoms (SANS)
(Andreasen, 1989) and the Scale for the Assessment of Positive Symptoms (SAPS) (Andreasen
et al., 1990) were used for the effect sizes of both negative and positive schizophrenic symptoms
respectively.
Cohen‘s D was used to assess the impact of the treatments (Ferguson, 2009), 0.2, 0.5 and 0.8
showing either a small, medium or large effect respectively. Confidence intervals and Standard-
ised Mean Deviations (SMD) were presented in the forest plots. A funnel plot and quantile-quantile
plot was also generated to assess publication bias of the trials included in the meta-analysis. Com-
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parison of trials lasting < 10 weeks and >10 weeks were compared to assess the impact of trial
length on treatment efficacy as well as comparison of the same atypical agents.
The R statistical analysis software was used in conjunction with the RStudio Editor, the Metafor
package was used in the generation of the forest plots and the funnel plot using a random ef-
fects model. We used the Standardised Mean Difference, giving the meta-analysis the ability to
compar the outcome of all the trials together regardless of the rating scale. Forest plots were
generated in order to gain an overall effect size for the combination of the atypical antipsychotic
with clozapine in regards to overall, negative and positive symptoms.
Results
The initial search revealed 1,412 studies, after the inclusion and exclusion criteria was applied, a
total of 10 studies with 588 patients (age range 18-65, average 35.3, 378 males and 210 females)
were included. Randomised controlled trials included four atypical antipsychotics combined with
clozapine, sertindole (n=1), olanzapine (n=1), aripiprazole (n=3) and risperidone (n=5) against a
placebo. Trial characteristics used are given in figure 1.
The effect size (95% Confidence Intervals) in figure 1 for the impact of treatment on overall
symptoms was -0.30 [-0.57, -0.02], for the impact of treatment on negative symptoms was -0.18
[-0.46, 0.11] in figure 3 and the impact of treatment on positive symptoms was -0.25 [-0.81, 0.30]
in figure 4. The funnel plot, figure 2 and the quantile-quantile plot in figure 3 showed no obvious
publication bias.
The standardised mean differences for overall change in BPRS/PANSS, negative and positive
symptoms found were of small improvement, -0.19, -0.18 and -0.25 respectively. This showed
that the combination of clozapine with a second generation antipsychotic, seen in figure 1, 2 and
3 showed a small improvement in patient‘s symptoms. So far this is the only meta-analysis to
look solely at the efficacy of second generation antipsychotics combined with clozapine. Previous
analyses (Taylor et al., 2012) looked at the combination of both typical and atypical antipsychotics
with clozapine treatment. Similar to this study, an effect size of 0.239, showed small effect of co-
therapy over monotherapy. Comparison of effect sizes of both first and patient symptomatology
showed there is no distinct difference between the efficacy of either class of drugs.
A systematic review (Correll et al., 2009) assessed antipsychotic combinations of first and second
generation antipsychotics including clozapine as a part of the combination against monotherapy
in schizophrenia. This study showed that antipsychotic combination therapy was favourable com-
pared to the control. In all the studies patients had been diagnosed using DSM-IV, and had been
trialled, unsuccessfully on two or more previous antipsychotics before the initiatio of clozapine.
4.1 Overall change in BPRS/PANSS
The forest plot in figure 1 was generated using a random effects model. It can be seen from the
effect size that only two trials (Muscatello et al., 2011) and (?) completely favored co-therapy
compared to the other trials in our study.
The forest plot in figure 1, indicates the standardised mean differences (SMD) for the individual
outcomes of each trial, the black diamond indicates the overall SMD for the meta-analysis (-0.30),
this effect size indicates a small favour of cotherapy. Examining the results from previous meta-
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Figure 1: Forest plot indicating effect of each trial and overall outcome using a random effects
model
analyses in this area and systematic reviews, the value does not differ greatly (Taylor et al., 2012)
and (Taylor and Smith, 2009), indicating that overall the combination of antipsychotics, which is
often used in clinical practice, is only of small effect (Correll et al., 2009).
Figure 2 displays a funnel plot which is intended to highlight publication bias, larger studies with
higher power are placed towards the top and lower powered studies are placed near the bottom.
The funnel plot, is generally symmetrical with three trials outside the funnel triangle (Fleischacker,
Honer and Yagcioglu) indicating heterogeneity but not necessarily publication bias.
Common flaws in treatment during trials which may affect bias shown in the funnel plot in-
clude; failure in randomization, poor blinding or large number of patients which are lost through
follow up (Taylor and Smith, 2009). The heterogeneity of this meta-analysis was moderate-to-high
(I2= 61.82%) variability within the trials, using a random effects model. The full statistics output for
the analysis is given below:
Random-Effects Model (k = 10; τ2 estimator: Random Effects)τ2 (estimated amount of total heterogeneity): 0.1120 (SE = 0.0896)τ (square root of estimated τ2 value): 0.3346I2 (total heterogeneity / total variability): 62.11%H2 (total variability / sampling variability): 2.64
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Figure 2: Funnel plot for the random effects model, indicating heterogeneity for some studies
Test for Heterogeneity:
Q(df = 9) = 25.3604, p-val = 0.0026
Where: τ is the between studies standard deviation and τ2 is the between studies variance of
the true effect sizes, I2 is the ratio of true heterogeneity to total observed variation, H2 is the is
the square root of the chi-square heterogeneity statistic divided by its degrees of freedom, Q is
Cochran’s statistic for estimating a measure of weighted squared deviations. Interpreting the val-
ues for I2 are usually low at 25%, moderate at 50% and high at 75% based on work by Higgins
(Higgins et al., 2003).
We investigated these potential problems further by plotting a quantile-quantile diagram, the stud-
ies should lie on the diagonal line with slope of 1, going through the (0,0) point. Deviations from
this may indicate that (a) the (residual) heterogeneity in the true effects is non-normally distributed,
(b) there are subgroups in the data that are not adequately modeled, and/or (c) that publication
bias is present. We observe that the most of the studies are close the the diagonal and the three
studies outside the original funnel plot are well within the confidence intervals.
4.2 Trials with aripiprazole
For the trials where aripiprazole combinations were used both groups showed favour of combi-
nation therapy. (Muscatello et al., 2011) Only one trial showed significant change in effects size
compared to all trials within this meta-analysis. This could be due to several factors; a)patients
may have been stabilised longer on clozapine although have partial response to the drug, b)longer
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Figure 3: quantile-quantile plot of study heterogeneity
trial length (24 weeks) c) Higher aripiprazole dose. Patients in this trial were allowed to take Lo-
razepam 5mg/day for insomnia or agitation. This may not have been acceptable in the other trials
in this meta-analysis. However patients did not receive any antidepressants or anticonvulsants
two months prior to this trial.
Aripiprazole augmentation in the second trial (Chang et al., 2008) had an effect size of -0.12,
which implied a small change in the rating scale used, however in the conclusion of the study
it was stated there was no improvement to overall BPRS rating however had a larger effect on
patient‘s negative symptoms. In comparison to Muscatello, the study lasted only 8 weeks. This
may have potentially affected the outcome of the trial even though it has been stated that 6 weeks
is sufficient enough time for a patient to be treated with an antipsychotic. The study by Fleis-
chhacker was included our analysis, (Fleischhacker et al., 2010) this work investigated the effect
of combined aripiprazole and clozapine on the weight in patients. PANSS was measured in pa-
tients as a secondary outcome, this availed no effect in the forms of clinical efficacy. Primary
outcomes of this trial included mean change in body weight from baseline to week 16. From the
primary outcome, aripiprazole-treated patients also showed a statistically significant difference in
weight loss as well as a reduction in BMI, total and low-density lipoprotein. As weight gain and
susceptibility of metabolic disorders increases when a patient is taking clozapine, the outcome of
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this trial is beneficial for patients.
Aripiprazole has a slightly different mechanism of action compared to other atypical antipsychotics.
It is a partial D2 and 5-HT2 agonist which means it does not bind fully to the receptor. Clozapine
binds to several receptors, D1-D5 and 5-HT2, as well as other receptors. Due to aripiprazole not
fully binding to the receptor site, it is not competing with clozapine for that site and it is not causing
the mol cules to dissociate. The slight difference in the receptor profiles of these two drugs indi-
cates why both trials had an effect size in preference of the combination treatment.
4.3 Trials with risperidone
In the trials where risperidone was combined with clozapine, it can be seen none of effect sizes
of these trials is as significant as Muscatello‘s (Muscatello et al., 2011). Two trials (Weiner et al.,
2010) and (Freudenreich et al., 2007) showed favour of the clozapine and risperidone combina-
tion. However, compared to the other two studies (Honer et al., 2006) and (Yagcioglu et al., 2005)
where monotherapy was favoured there was no difference in the dose of the add-on drug which
was 4mg/day. Therefore it is with difficulty to say where the changes in efficacy have arisen from.
Randomised, controlled trials involving risperidone lasted a range of 6-16 weeks. Trials which
lasted less than ten weeks did not show efficacy for the combinations used. risperidone, like
clozapine, is an antagonist at both D2 and 5-HT2 receptor sites (Golan et al., 2007). Both drugs
are competing for the same sites to bind to, this indicates why only some trials may have had an
effect size in favour of co-therapy.
The problems with risperidone may have arisen where the patients had previously been trialled
on this drug and were deemed unresponsive, or the patient was unable to tolerate the combina-
tions. Another factor which may have affected trial outcome, was the sample size. Those with the
diagnosis of schizophrenia may respond to a first or a second generation anti-psychotic without
ever having to be treated with clozapine which is reserved for patients deemed to have refractory
schizophrenia. Therefore, those patients who are treated with clozapine is a smaller sample than
those who may have responded to prior treatment. This indicates that unless a multicentre trial,
large sample sizes in randomised controlled trials where patients are treated with clozapine may
be very difficult to find.
4.4 Trial with Olanzapine
The study undertaken by Constantine involved randomly switching the co-therapy patients to a
clozapine + placebo, leaving the other patients to a clozapine+olanzapine therapy (Constantine
et al., 2015). The initial motivation for this trial was to overcome certain polypharmacy issues in-
volved with the treatment of schizophrenia. The followup investigation was longer than most trials
and at the end of 360 days the patients PANNS score was more or less stable. The trial tended to
suggest that those who stayed on co-therapy had better outcomes, while those who switched to
clozapine alone appeared to have a n increase in positive symptoms
4.5 Trial with Sertindole
The study by Nielsen using a combination of clozapine and sertindole did not improve or worsen
their cognitive functions, they discuss that sample size may be an issue but admit their studies
results are comparative to the other studies (Nielsen et al., 2012) Their choice of sertindole was
motivated by it’s low levels of sedation and seemed therefore an ideal cotherapy. However, after
the 12 week trial was over, the results did not indicate any correlation between cognitive function
and psychopathology as highlighted by the PANNS and GAF and CGI scores.
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4.6 Trials lasting longer than 10 weeks and Trials shorter than 10 weeks.
Work by Taylor compared trials of less than 10 weeks in length to those longer than 10 weeks. A
meta-regression plot was produced in order to see the relationship between the effect size and trial
length (Taylor et al., 2012). Randomised controlled trials lasting longer than ten weeks showed a
marginal increase in effect size (-0.223) when compared to those less than ten weeks in length
(-0.103). This indicates that for a trial where clozapine is combined with a second drug, a longer
trial, ideally ≥10 weeks, this coincides with guidance (NICE178, 2014) recommending a trial of
combination treatment to last at least 8-10 weeks. This will allow patients to become accustomed
to adhering to two different medications.
When comparing studies which lasted longer than 10 weeks (Muscatello et al., 2011) and (Weiner
et al., 2010) it was possible to see a larger effect size when compared to those of a shorter dura-
tion. Both trials lasting long than ten weeks exhibited an effect size larger than -0.19, this indicates
that the efficacy of the trials ranged from moderate to large. Effect size may have been affected if
sample size was smaller than 30, or if the trial was biased in any way. Barbui et al (Barbui et al.,
2009) found within the systematic review the effect size of none blinded trials was larger than the
trials where double blinding was involved.
Studies that lasted less than 10 weeks varied in their favour of combination therapy over monother-
apy. Two studies (Chang et al., 2008) and (Freudenreich et al., 2007) showed favor of combination
treatment over monotherapy. Monotherapy was favoured in the other two studies (Honer et al.,
2006) and (Yagcioglu et al., 2005). Again this may have been due to several factors; firstly, the
patient may not have responded to the medication. Secondly, the patient may have been non-
adherent or have a problem with compliance. Thirdly, the patient may have insufficient clozapine
levels due to taking a second atypical antipsychotic.
4.9 Limitations
There are several limitations to this meta-analysis including the small number of patients recruited
to several of the trials. The mean sample size of the trials was 69.2 (range 24-204, median 56),
trials of less than 30 participants do not reflect well in effect size calculations due to the small
range of results. This is likely to give the trial less power to change or show any significance, small
trials are likely to be more biased via giving a larger effect than large multicentre studies.
Another limitation of the analysis is the small number of trials conducted using atypical antipsy-
chotics in combination with clozapine for treatment resistant patients. Only studies including arip-
iprazole (3), sertindole (1), olanzapine (1) and risperidone (5) could be analysed.
This analysis looks at the efficacy of a second generation antipsychotic drug combined with cloza-
pine for patients with refractory schizophrenia. Other therapies have been used to treat refractory
schizophrenia with either some or little improvement in patient‘s symptoms. These include; ECT,
CBT, combinations with different classes of drugs; mood stabilisers and antidepressants. It was
not possible nor appropriate to include such studies into our analysis
Conclusions
The treatment of refractory schizophrenia is a common activity for mental health professionals.
Schizophrenia places demands on and adversely effects the quality of life, social aspects and the
patients ability to work. It is often a disorder that is associated with co-morbidities. Buckley found
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that co-morbidities such as substance abuse, anxiety, depression, panic disorder, post-traumatic
stress disorder and obsessive compulsive disorder were highly prevalent among schizophrenic
patients (Buckley et al., 2009). These have further effects upon the patient from medication to
quality of life (Dold and Leucht, 2014).
Other factors to consider in regards to combination treatments, is the possible increased risk of
adverse reactions when combining two drugs from the same class. All second generation antipsy-
chotics come with an increased risk of weight gain and metabolic side effects. The only exception
to this was (Fleischhacker et al., 2010) where the addition of aripiprazole to clozapine reduced
weight, BMI and lipid profile in patients. Finally, it has been found through statistical techniques
that combination of a second generation antipsychotic with clozapine, the gold-standard treatment
for schizophrenia, is only marginally beneficial. The therapy may show some improvement within
individual patients however, the overview of the therapy as a whole, is not beneficial for the group.
Therefore, it is the recommendation of this analysis that alternative medications be sought in order
to treat patients who have a sub-optimal response to clozapine with a combination other than two
second generation antipsychotics. This route should only be used once all other treatment options
have been exhausted.
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Study (year) Characteristics Trial length 
(weeks)
No of patients 
starting trial (M/F)
Control / placebo Mean age years 
(range)
Drug patients stopped prior to trial or medications 
which warranted exclusion
Drugs patients had access to while on trial Applicable outcomes measured
Yagcioglu (2005) Turkey Patients were diagnosed with schizophrenia using DSM-IV. Entry into the trial was based on total 
PANSS score of at least 72, a CGI-S score of at least 4 and at least 3 on any 1 of the PANSS POS (0-7) 
scale. Patients who had been on clozapine for at least 6 months were entered into the trial. Clozapine 
doses ranged between 300-900 mg/day. Risperidone up to 6 mg/day was used for patients in the 
control arm of the trial. 
6 30 (20/10) 15 in control and 14 
in placebo
35.3 (18-55) mood stabilisers, lithium, antidepressants, and/or 
antipsychotics  other than clozapine. 
Benzodiazepines (clonazepam 0.5 - 2.0 mg/day) were 
used to treat anxiety, and biperiden (2-6 mg/day) was 
used to treat EPSE. 
PANSS
Josiassen (2005) USA Patients were diagnosed with schizophrenia or schizoaffective disorder using DSM-IV.  Clozapine use 
for 12 weeks with poor response. BPRS of 45 or 4 or more criteria on 2-4 BPRS positive symptom 
items. Clozapine dose of 528mg/day for risperdone group and 402.5 mg/day for placebo.
12 40(35/5) 20 control and 20 in 
placebo
40.3 (20-65) N/A N/A BPRS, CGI, SANS
Honer (2006) Canada, 
Germany, China, UK
Patients were diagnosed with schizophrenia using DSM-IV. Entry into the trial was based on a total 
PANSS score of 80 or more, at least 4 or more on CGI and a SOFAS score of 40 or less. Patients had 
been on a stable dose of clozapine 400 mg/day or more for at least 12 weeks. Risperidone was given 
to the control group at a mean dose of 2.95 mg/day.
18 68 (50/18) 34 in control and 34 
in placebo
37 (18-65) Treatment with clozapine for movement disorder or 
of intolerable side effects from other medications.  
Previous treatment with risperidone. Patients were 
required to discontinue any drugs other than 
clozapine (mood stabilisers or anti-depressants or 
anti-convulsants) two weeks before the trial. 
Any drugs being used to treat stable medical issues 
were permitted. 
PANSS
Freudenreich (2007) USA Patients were diagnosed with schizophrenia using DSM-IV. Entry into the trial was based on the 
patients have a PANSS score of greater than 60. Patients in the trial had been treated with clozapine 
for at least 6 months and had been on a stable dose for at least 8 weeks. Clozapine doses ranged from 
200-700 mg/day. A 4 mg/day fixed dose of risperidone was given to those patients assigned to the 
control group. 
6 24 (21/3) 11 control, 13 
placebo
42.3 (27-55) N/A N/A PANSS and SANS
Chang (2008) Korea Patients were diagnosed with schizophrenia using DSM-IV. Entry into the trial was based on patients 
have a BPRS score of at least 35 or more than two on the SANS rating. Patients in the trial had been 
treated with clozapine at least one year prior to the study with at least 8 weeks on a stable dose of 
400 mg/day or more. Patients in the treatment arm of the trial were given an aripiprazole dose of at 
least 30 mg/day. 
8 62 (49/13) 30 in control and 32 
in placebo
33.2 (18-65) Prior history of non-response or tolerance to 
aripiprazole, participation in a clinical trial of 
another investigational drug within 3 months of the 
study
Concomitant medications for stable medical conditions 
including antidepressants, anticholinergics and 
benzodiazepines.  
BPRS and SANS
Fleischacker (2010) USA, 
France, Finland, UK, 
Austria 
Patients were diagnosed with schizophrenia using DSM-IV-TR criteria such as weight gain of more than 
2.5Kg  and safety issues on clozapine. Clozapine dose of 362.6 mg/day and 383.8 mg/day for 
aripiprazole.
16 205(106/99) 106 control and 99 
in placebo
40.5 (18-65) patients at risk of suicide excluded. Exculded for use 
of psychoactive substance use disorder.
Benzodiazepines  and anticholinergics were allowe any 
time and also sleeping aids. Antidepressants and mood 
stabilizers were also allowed if prescribed before entry 
into study.
PANNS, CGI and weight
Weiner (2010) USA Patients were diagnosed with schizophrenia using DSM-IV. Entry into the trial was based on patients 
having a total BPRS score of 45 or more, a CGI score of 4 or more and a BPRS positive symptom score 
of 8 or more. Patients were required to have had an adequate clozapine trial for 6 or more months on 
a dose that produced a plasma level of 350 mg/mL of more. Risperidone was given at 4 mg/day. 
16 69 (44/25) 33 in control and 36 
in placebo
44.4 (18-65) Patients treated previously with adjunctive 
risperidone at more than 8 mg/day for at least 6 
weeks were excluded. 
N/A BPRS and SANS
Muscatello (2011) Italy Patients were diagnosed with schizophrenia using DSM-IV. Entry into the trial was based on patients 
have a BPRS score or 25 or more. Patients had been on the highest tolerable dose of clozapine for at 
least one year and doses in the range of 200-450 mg/day had been stable for at least one month. 
Aripiprazole was given at an initial dose of 10 mg/day and increased to 15 mg/day. 
24 40 (23/17) 20 in control and 20 
in placebo
31.9 (25-38) N/A Patients were allowed to take lorazepam up to 5 
mg/day for insomnia and agitation. 
BPRS, SANS and SAPS
Nielsen (2012) Dennmark Patients diagnosed with  schizophrenia  and treated with clozapine for 6 months and scored at least 
65 on PANNS at baseline. Doses of clozapine were 394mg/day for sertindole and 435.o mg/day for 
placebo.
12 50(30/20) 25  in control and 25 
in placebo
41.8 (18-65) N/A Benzodiazepines  and anticholinergics were allowe any 
time and also sleeping aids. Antidepressants and mood 
stabilizers were also allowed if prescribed before entry 
into study.
PANNS, UKU and CGI
Constantine (2015) USA Patients were diagnosed with schizophrenia using DSM-IV-TR criteria who had been receiving 2 
medications concurrently for at least 90 days. 
52 104(50/54) 25 in control and 41 
in placebo
43.9 (18-64) Patients who had recent hopspitalization or 
emergency room visits in 90 days.
PANNS and CGI
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RE Model
-3 -2 -1 0 1
Standardized Mean Difference
Constantine, 2015
Nielsen, 2012
Muscatello, 2011
Fleischhacker, 2010
Weiner , 2010
Chang, 2008
Freudenreich, 2007
Honer, 2006
Josiassen, 2005
Yagcioglu, 2005
-0.24 [-0.66,  0.17]
 0.00 [-0.55,  0.55]
-0.96 [-1.71, -0.22]
-0.75 [-1.04, -0.47]
-0.46 [-1.01,  0.09]
-0.12 [-0.62,  0.38]
-0.56 [-1.38,  0.26]
 0.27 [-0.22,  0.76]
-0.60 [-1.23,  0.03]
 0.49 [-0.23,  1.22]
-0.30 [-0.57, -0.02]
Study/Source Observed SMD [95% CI]
Favours co-therapy Favours mono-therapy
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Random−Effects Model
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Reviewer(s)' Comments to Author: 
Reviewer: 1 
Comments: 
My review and additional suggestions regarding the article entitled  “Combination of Clozapine with 
an Atypical Antipsychotic: A Meta-Analysis” are listed below: 
1)      Corrections and suggestions have been made on the original manuscript, attached to this file. 
2)      In the introduction section: 
- Clozapine is mentioned to be reserved for treatment resistant patients, “due to agranulocytosis 
and metabolic side effect profile”. The reservation is related to haematological but not metabolic 
side effects. This should be corrected. Changed wording 
- Current definition of treatment resistant schizophrenia should be commented on (Howes et al., Am 
J Psychiatry. 2016). Short definition included based on this reference added. 
- In addition to general antipsychotic polypharmacy, the basis for clozapine augmentation in 
treatment resistant schziophrenia patients should also be mentioned. 
3)      In the methods and results section: 
-The study of Anil Yagcioglu et al. 2005 has been incorrectly referred as Barbui et al 2009 in several 
places in the manuscript (some corrected on text). Changed citations appropriately. 
    4) In the conclusion section: 
-1. paragraph: Here, comorbidity issue is discussed. Final sentence in this paragraph has no 
relevance to comorbidity. Removed paragraph. 
-2. paragraph: “It was assumed that patients in these 6 trials were treatment resistant”. The 
definition of treatment resistance and sample selection in these particular 6 studies should be 
reviewed and discussed, leaving no room for assumption. 
As far as we are able to determine all the patients were deemed treatment resistant, we have 
reworded our discussion to reflect this. 
-4. paragraph: It is stated that combination treatment “may have increased the risk of adverse 
events”. The safety findings of these 6 studies should be evaluated and pointed out in the discussion, 
if safety issue is to be discussed. 
Examining the literature we can find little evidence that the combination therapy incre ses the 
possibility of adverse effects and have reworded this section to reflect that.  
-5. pararaph: Here, there is a vague mention of the cost-benefit issue of using combined 
antipsychotics. Although cost of two antipsychotic treatments being used at the same time is 
mentioned as a drawback, the cost of hospitalization when treatment resistance is the main issue is 
not discussed. If this issue is not to be discussed presenting study findings relevant to cost, it should 
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rather be not discussed. On reflection, the cost benefit issues discussion has been removed as it is 
not central to our work and is a distraction.  
Additional Questions: 
1. Originality:  Does the paper contain new and significant information adequate to justify 
publication?: This meta-analytical study specifically investigates the outcome of combining clozapine 
with other atypical antipsychotics in schizophrenia patients.  As it includes new studies which had 
not been earlier included in the most recent meta-analysis study  exploring the same subject (Taylor 
et al., Acta Psychiatrica Scandinavia 2012), I believe it could contribute to current literature. 
2. Relationship to Literature:  Does the paper demonstrate an adequate understanding of the 
relevant literature in the field and cite an appropriate range of literature sources?  Is any significant 
work ignored?: There are other randomized placebo controlled studies investigating the addition of 
an aytpical antipsychotic to clozapine in treatment resistant schizophrenia patients, which meet the 
inclusion criteria mentioned in this study (eg: addition of  amisulpiride-Assion et al. 2008, sulpiride- 
Shiloh et al 1997, sertindole -Nielsen et al. 2012). The reason why such studies of clozapine 
combinations are left out should be made clear.  
The issue of related literature i.e. why had not the Assion, 2008; the Shiloh, 1997 and the Niesen, 
2012 papers had not been included. The Shiloh study uses sulpiride which is a 1
st
 generation 
antipsychotic drug and therefore not within our remit which focuses on 2
nd
 generation antipsychotic 
drugs.  The Assion paper presents problems, although it falls into our remit and should be included, 
however certain data are not available within the paper to incorporate into our analysis. The lead 
author (Assion) has not responded to emails. 
3. Methodology:  Is the paper's argument built on an appropriate base of theory, concepts, or other 
ideas?  Has the research or equivalent intellectual work on which the paper is based been well 
designed?  Are the methods employed appropriate?: Yes. 
4. Results:  Are results presented clearly and analysed appropriately?  Do the conclusions adequately 
tie together the other elements of the paper?: It is not clear whether the impact of all 6 randomized 
controlled studies has been included in the assessment of change in positive and negative 
symptoms. Figures 2 and 3 include studies with SANS and SAPS, and therefore Anil Yagcioglu et al 
2005 study has been omitted in these figures. However, Honer et al 2006 study has been included in 
Figures 2 and 3, although the rating in that study has also been done with PANSS. 
The positive and negative forest plots have been removed, a few studies did not give a breakdown of 
the main effects into positive and negative values for PANNS etc.   
The conclusion needs to be further worked on, details of which are presented in my additional 
comments. We added new material and edited the conclusions for clarity. 
5. Practicality and/or Research implications:  Does the paper identify clearly any implications for 
practice and/or further research?  Are these implications consistent with the findings and 
conclusions of the paper?: Yes. 
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6. Quality of Communication:  Does the paper clearly express its case, measured against the 
technical language of the field and the expected knowledge of the journal's readership?  Has 
attention been paid to the clarity of expression and readability, such as sentence structure, jargon 
use, acronyms, etc.: Review of this article regarding clarity and correctness of English is necessary. 
We have had the paper proof read and have improved the quality of the writing. 
Reviewer: 2 
Comments: 
This doesn't seem to have anything new to offer and the non-significant results are misrepresented 
as definitive findings. 
We have added additional trials to the last known meta-analysis on clozapine. 
Additional Questions: 
1. Originality:  Does the paper contain new and significant information adequate to justify 
publication?: No 
2. Relationship to Literature:  Does the paper demonstrate an adequate understanding of the 
relevant literature in the field and cite an appropriate range of literature sources?  Is any significant 
work ignored?: Yes 
3. Methodology:  Is the paper's argument built on an appropriate base of theory, concepts, or other 
ideas?  Has the research or equivalent intellectual work on which the paper is based been well 
designed?  Are the methods employed appropriate?: Sort of, but it's been done before 
As we have already indicated we have added the latest research. 
4. Results:  Are results presented clearly and analysed appropriately?  Do the conclusions adequately 
tie together the other elements of the paper?: Yes 
5. Practicality and/or Research implications:  Does the paper identify clearly any implications for 
practice and/or further research?  Are these implications consistent with the findings and 
conclusions of the paper?: No 
6. Quality of Communication:  Does the paper clearly express its case, measured against the 
technical language of the field and the expected knowledge of the journal's readership?  Has 
attention been paid to the clarity of expression and readability, such as sentence structure, jargon 
use, acronyms, etc.: It's good but I don't see the point. 
It all hinges on the point of the additional studies, we have added four more studies. 
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